What insurance policy changes affect code N88.3?

There are 3 tracked policy changes affecting code N88.3, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code N88.3?

Payers that have issued tracked updates for code N88.3 include: Aetna.

How do I get notified when code N88.3 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code N88.3. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code N88.3?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

N88.3 Insurance Policy Changes

ICD-10 N88.3 is officially defined as "Incompetence of cervix uteri." code N88.3 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code N88.3 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 5, 2026Medium impact
Transabdominal Cerclage (CPB 0529, reviewed 2026-08-28)
Aetna's Clinical Policy Bulletin 0529 treats transabdominal cerclage as medically necessary for an incompetent cervix when the patient has a deep traumatized cervix, a previous failed cervical (transvaginal) cerclage, a shortened (less than 2.5 cm) or amputated cervix, or when the cerclage is placed before conception via laparoscopy or laparotomy. Aetna considers transabdominal cerclage experimental, investigational or unproven for all other indications, such as prophylactic cerclage for multiple gestations. A history consistent with incompetent cervix must be documented to establish medical necessity, including a history of mid-trimester pregnancy loss associated with painless cervical dilatation without evidence of uterine activity.
Aetna · Identified Aug 18, 2026Medium impact
Transabdominal Cerclage (CPB 0529, reviewed 2025-11-25)
Aetna considers transabdominal cerclage medically necessary for treating an incompetent cervix when any of these apply: a deep traumatized cervix; previous failed transvaginal cerclages; a shortened (less than 2.5 cm) or amputated cervix; or transabdominal placement for cervical incompetence before conception by laparoscopy or laparotomy. A history consistent with incompetent cervix must be documented, including a history of mid-trimester pregnancy loss associated with painless cervical dilatation without evidence of uterine activity. Aetna considers transabdominal cerclage experimental, investigational, or unproven for all other indications, such as prophylactic cerclage for multiple gestations.
Aetna · Identified Aug 17, 2026Medium impact
Fetal Fibronectin, Inflammatory Biomarkers, and Salivary Hormone Testing for Preterm Labor (CPB 0166, reviewed 2026-04-21)
Aetna considers the fetal fibronectin (fFN) immunoassay medically necessary to evaluate pregnant women with symptoms of preterm labor who are considered high-risk for preterm delivery when amniotic membranes are intact, cervical dilation is less than 3 cm, sampling occurs no earlier than 24 weeks 0 days and no later than 34 weeks 6 days of gestation, and results will be available quickly enough to influence real-time decisions for suspected preterm labor. A repeat fFN immunoassay is medically necessary when the member meets all of the same criteria and remains symptomatic 2 or more weeks after a previous negative fFN immunoassay. Fetal fibronectin testing for routine screening of the general obstetric population, for asymptomatic high-risk women, for identifying optimal cerclage candidates, and following cervical cerclage insertion is experimental, investigational or unproven, as are the biomarker, inflammatory marker, proteomic, metabolomic and salivary hormone tests named for preterm birth prediction.

Watch N88.3

Get one email when a payer policy names N88.3, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Transabdominal Cerclage (CPB 0529, reviewed 2026-08-28)

Transabdominal Cerclage (CPB 0529, reviewed 2025-11-25)

Fetal Fibronectin, Inflammatory Biomarkers, and Salivary Hormone Testing for Preterm Labor (CPB 0166, reviewed 2026-04-21)

What insurance policy changes affect code N88.3?

Which payers have updated policy for code N88.3?

How do I get notified when code N88.3 policy changes?

Why do payers change policies for code N88.3?